1. Clinical & Scientific Overview
Pomalidomide (TIP-MED-000545, Reference Code [R-26]) is classified under
Relapsed/Refractory Multiple Myeloma as a Third-Generation Cereblon-Binding Immunomodulatory Agent (IMiD).
Within the Indian regulatory and compendial framework, it is governed under Schedule H1 + Pregnancy Prevention Control (High-Alert Teratogen).
Pomalid (Natco Pharma), Pomide (Hetero Healthcare), Pomabuzz (Cipla Ltd)
Hard Gelatin Capsule: 1 mg, 2 mg, 3 mg, 4 mg
Statutory Restriction, High-Alert & Dispensing Safeguards
Indian Regulatory & Statutory Control Basis: Schedule H1 + Pregnancy Prevention Control (High-Alert Teratogen)
High-Alert Clinical Risk, Dependence & Narrow Therapeutic Index Warnings: Severe teratogenicity, Grade 3/4 neutropenia (48%), venous thromboembolism, and CYP1A2-mediated metabolism (avoid strong CYP1A2 inhibitors such as fluvoxamine or ciprofloxacin, and advise against smoking which induces CYP1A2).
Mandatory Dispensing Register & Institutional Custody Protocol: Enforce Thalidomide/Lenalidomide-equivalent pregnancy prevention safeguards, mandatory VTE prophylaxis, and ANC monitoring before each 28-day cycle.
3. Mechanism of Action & Pharmacodynamics
High-potency cereblon modulator that degrades IKZF1 and IKZF3 even in lenalidomide-resistant myeloma clones, restoring immune synapse formation and inducing apoptosis.
4. Therapeutic Indications & Evidence-Supported Uses
- Relapsed and refractory multiple myeloma after at least two prior therapies including lenalidomide and bortezomib
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Specialist-Supervised Educational Reference Summary: Dosing of Pomalidomide must be individualised by a qualified specialist according to clinical indication, organ function, and institutional protocol (Hard Gelatin Capsule: 1 mg, 2 mg, 3 mg, 4 mg).
Administration & Meal Timing: Routes: Oral (4 mg once daily on Days 1–21 of repeated 28-day cycles). Enforce Thalidomide/Lenalidomide-equivalent pregnancy prevention safeguards, mandatory VTE prophylaxis, and ANC monitoring before each 28-day cycle.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Exhibits third-generation cereblon-binding immunomodulatory agent (imid) pharmacokinetic disposition; verify baseline renal and hepatic clearance and check for active or prolonged-half-life metabolites before repeat dosing.
Hepatic Phase I (CYP450) and/or Phase II conjugation or specific non-renal clearance as detailed in clinical warnings.
Verify eGFR / CrCl before initiation; see specific metabolite and renal clearance notes above.
Assess baseline Child-Pugh status and hepatic transaminases prior to therapy.
7. Contraindications, Precautions & High-Risk Warnings
- Known severe hypersensitivity to Pomalidomide or formulation excipients
- Unsupervised outpatient self-administration or dispensing without mandatory statutory prescription verification
- Specific clinical contraindications detailed under High-Alert Warnings & Statutory Restrictions
Key Clinical Precautions: Severe teratogenicity, Grade 3/4 neutropenia (48%), venous thromboembolism, and CYP1A2-mediated metabolism (avoid strong CYP1A2 inhibitors such as fluvoxamine or ciprofloxacin, and advise against smoking which induces CYP1A2).
8. Adverse Effects Profile
- Severe teratogenicity, Grade 3/4 neutropenia (48%), venous thromboembolism, and CYP1A2-mediated metabolism (avoid strong CYP1A2 inhibitors such as fluvoxamine or ciprofloxacin, and advise against smoking which induces CYP1A2).
- Dose-dependent target-organ pharmacodynamic effects requiring clinical observation
- Severe teratogenicity, Grade 3/4 neutropenia (48%), venous thromboembolism, and CYP1A2-mediated metabolism (avoid strong CYP1A2 inhibitors such as fluvoxamine or ciprofloxacin, and advise against smoking which induces CYP1A2).
- High-alert toxicity, dependence/diversion risk, or severe organ-specific adverse events if administered outside protocol
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Severe teratogenicity, Grade 3/4 neutropenia (48%), venous thromboembolism, and CYP1A2-mediated metabolism (avoid strong CYP1A2 inhibitors such as fluvoxamine or ciprofloxacin, and advise against smoking which induces CYP1A2).
- Review all concomitant CNS depressants, QTc-prolonging agents, nephrotoxins, or CYP450 modulators prior to dispensing.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Enforce Thalidomide/Lenalidomide-equivalent pregnancy prevention safeguards, mandatory VTE prophylaxis, and ANC monitoring before each 28-day cycle.
Pharmacist Patient Counselling Points:
- Enforce Thalidomide/Lenalidomide-equivalent pregnancy prevention safeguards, mandatory VTE prophylaxis, and ANC monitoring before each 28-day cycle.
- Must be used strictly under direct medical supervision; never share prescription medicines or alter the prescribed dose.
Storage, Stability & Dispensing Safeguards: Enforce Thalidomide/Lenalidomide-equivalent pregnancy prevention safeguards, mandatory VTE prophylaxis, and ANC monitoring before each 28-day cycle.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Drugs and Cosmetics Act, 1940 & Rules, 1945 (Schedule H / H1 / X); NDPS Act, 1985 & Essential Narcotic Drugs (END) Notification; Indian Pharmacopoeia (IP) & National Formulary of India (NFI).
Official Verification Portals: CDSCO — Drugs & Cosmetics Act and Rules (Schedules H, H1, X) • Department of Revenue — Narcotic Drugs and Psychotropic Substances (NDPS) Act • Indian Pharmacopoeia Commission (IPC) — National Formulary of India
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [R-02] Pentazocine Lactate / Hydrochloride — Mixed Opioid Agonist-Antagonist Analgesic
- [R-03] Pethidine Hydrochloride (Meperidine) — Synthetic Phenylpiperidine Mu-Opioid Agonist
- [R-04] Methadone Hydrochloride — Synthetic Long-Acting Mu-Opioid Agonist & NMDA Antagonist
- [R-01] Buprenorphine (Sublingual & Transdermal) — Partial Mu-Opioid Agonist & Kappa-Opioid Antagonist